TY - JOUR
T1 - Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells
AU - Cascioferro, Stella Maria
AU - Cirrincione, Girolamo
AU - Diana, Patrizia
AU - Li Petri, Giovanna
AU - Parrino, Barbara
AU - Carbone, Daniela
AU - Peters, Godefridus J.
AU - Dekker, Henk
AU - Petri, Giovanna Li
AU - Mantini, Giulia
AU - Bergonzini, Cecilia
AU - Funel, Niccola
AU - Giovannetti, Elisa
AU - Geerke, Daan
PY - 2020
Y1 - 2020
N2 - A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized andscreened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Twoout of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the halfmaximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 mM, and 0.29e12.2 mM,respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferativeactivity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized(SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), eliciting IC50 valuesranging from micromolar to sub-micromolar level, associated with significant reduction of cell-migrationand spheroid shrinkage. These remarkable results might be explained by modulation of key regulators ofepithelial-to-mesenchymal transition (EMT), including E-cadherin and vimentin, and inhibition ofmetalloproteinase-2/-9. High-throughput arrays revealed a significant inhibition of the phosphorylationof 45 tyrosine kinases substrates, whose visualization on Cytoscape highlighted PTK2/FAK as animportant hub. Inhibition of phosphorylation of PTK2/FAK was validated as one of the possible mechanismsof action, using a specific ELISA. In conclusion, novel imidazothiadiazoles show potent antiproliferativeactivity, mediated by modulation of EMT and PTK2/FAK.
AB - A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized andscreened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Twoout of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the halfmaximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 mM, and 0.29e12.2 mM,respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro antiproliferativeactivity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized(SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), eliciting IC50 valuesranging from micromolar to sub-micromolar level, associated with significant reduction of cell-migrationand spheroid shrinkage. These remarkable results might be explained by modulation of key regulators ofepithelial-to-mesenchymal transition (EMT), including E-cadherin and vimentin, and inhibition ofmetalloproteinase-2/-9. High-throughput arrays revealed a significant inhibition of the phosphorylationof 45 tyrosine kinases substrates, whose visualization on Cytoscape highlighted PTK2/FAK as animportant hub. Inhibition of phosphorylation of PTK2/FAK was validated as one of the possible mechanismsof action, using a specific ELISA. In conclusion, novel imidazothiadiazoles show potent antiproliferativeactivity, mediated by modulation of EMT and PTK2/FAK.
UR - http://hdl.handle.net/10447/414864
M3 - Article
VL - 189
SP - 1
EP - 18
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
SN - 0223-5234
ER -